ALB and Hypoalbuminemia: Clinical chemistry parameter measurement showed a significant decline in albumin and total protein levels after Oncaspar administration, independent of the condition of the liver by inhibition of protein synthesis associated with the main mechanism of the drug.20 Hypoalbuminemia is one of the major abnormalities associated with Oncaspar treatment21 with a consequent hepatic toxicity.